Automatic Detection and Quantitative DCE-MRI Scoring of Prostate Cancer Aggressiveness

Nestor Andres Parra1, Alan Pollack1, Felix M. Chinea1, Matthew C. Abramowitz1, Brian Marples1, Felipe Munera2, Rosa Castillo2, Oleksandr N. Kryvenko3,4, Sanoj Punnen4 and Radka Stoyanova1*

1 Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, FL, United States, 2 Department of Radiology, University of Miami Miller School of Medicine, Miami, FL, United States, 3 Department of Pathology, University of Miami Miller School of Medicine, Miami, FL, United States, 4 Department of Urology, University of Miami Miller School of Medicine, Miami, FL, United States

Purpose: To develop a robust and clinically applicable automated method for analyzing Dynamic Contrast Enhanced (DCE-) MRI of the prostate as a guide for targeted biopsies and treatments.

Materials and methods: An unsupervised pattern recognition (PR) method was used to analyze prostate DCE-MRI from 71 sequential radiotherapy patients. Identified regions of interest (ROIs) with increased perfusion were assigned either to the peripheral (PZ) or transition zone (TZ). Six quantitative features, associated with the washin and washout part of the weighted average DCE curve from the ROI, were calculated. The associations between the assigned DCE-scores and Gleason Score (GS) were investigated. A heatmap of tumor aggressiveness covering the entire prostate was generated and validated with histopathology from MRI-ultrasound fused (MRI-US) targeted biopsies.

Results: The volumes of the PR-identified ROI’s were significantly correlated with the highest GS from the biopsy session for each patient. Following normalization (and only after normalization) with gluteus maximus muscle’s DCE signal, the quantitative features in PZ were significantly correlated with GS. These correlations straightened in subset of patients with available MRI-US biopsies when GS from the individual biopsies were used. Area under the receiver operating characteristics curve for discrimination between indolent vs aggressive cancer for the significant quantitative features reached 0.88–0.95. When DCE-scores were calculated in normal appearing tissues, the features were highly discriminative for cancer vs no cancer both in PZ and TZ. The generated heatmap of tumor aggressiveness coincided with the location and GS of the MRI-US biopsies.

Conclusion: A quantitative approach for DCE-MRI analysis was developed. The resultant map of aggressiveness correlated well with tumor location and GS and is applicable for integration in radiotherapy/radiology imaging software for clinical translation.

Keywords: prostate cancer, DCE-MRI, image processing, pattern recognition, mpMRI
INTRODUCTION

Prostate cancer is the second most common cancer in American men (1). Clinical decisions, related to the need for prostate biopsy, define target areas for biopsy and regions that require attention in focally directed therapy, are multifactorial and complex. Delivery of targeted radiation dose to high-risk tumor areas in lieu of escalating dose to the entire prostate will reduce overall complication risks (2), a strategy that requires robust and quantitative imaging of potential tumor lesions (3, 4).

The use of multiparametric MRI (mpMRI) for prostate cancer is rapidly evolving because of its growing availability and ability to combine functional [perfusion via dynamic contrast enhanced (DCE-MRI) and diffusion via diffusion-weighted imaging (DWI)], and anatomical information [T2-weighted (T2w) MRI]. DCE-MRI is an established component of prostate mpMRI, and DCE-MRI alone has reported sensitivity and specificity ranges of 46–96 and 74–96%, respectively (5–10). The role of DCE-MRI for tumor diagnosis and assessment in the current version of Prostate Imaging Reporting and Data System (PI-RADS) (version 2), however, is minimized (11). DCE-MRI is only considered when DWI in the peripheral zone (PZ) is indeterminate. The PI-RADS Steering Committee justified the reduced role of DCE-MRI in prostate cancer assessment by the lack of expert consensus, reflective of the difficulty of interpreting DCE-MRI sequences by eye. An automated and quantitative assessment has the potential to improve consistency in identifying high risk prostate volumes.

There has been considerable efforts to standardize the analysis of DCE-MRI (12, 13) with pharmacokinetic modeling (14); however, there is significant variability in the calculated rate constants. For instance, $K_{\text{trans}}$, the volume transfer coefficient that measures capillary permeability (14), calculated on the same DCE-MRI data by participants from several academic medical centers yielded a within-subject coefficient of variation of 0.59 (15). This modeling approach is impeded by difficulties in estimating the arterial input function (16), insufficient temporal resolution (17, 18) and low signal-to-noise ratio (SNR).

Previously, it has been shown that the application of pattern recognition (PR) techniques to DCE-MRI overcomes the challenges of low temporal resolution and low SNR (19–21). Here, the PR approach is extended by introducing novel quantitative features that allow for comparisons between patients. The method automatically: (i) delineates the region in the prostate with increased perfusion; (ii) allocates the dominant lesion to either the PZ or transition zone (TZ); (iii) assigns a DCE score—a zone-specific quantitative measure of aggressiveness; and (iv) generates a spatial map of tumor aggressiveness based on DCE score. The result is a color-coded map of aggressiveness on a pixel level, which may serve as a guide for targeted biopsies and treatments.

MATERIALS AND METHODS

Patients and MRI Acquisition

An Institutional Review Board (IRB) approved a protocol for retrospective review of mpMRI exams from prostate cancer patients. The IRB waived the need for informed consent. A total of 71 sequential patients, presenting for evaluation for radiation treatment (RT) between 2012 and 2015 and who underwent mpMRI exams on a 3T Discovery MR750 (GE, Waukesha, WI, USA) were identified from the departmental database.

mpMRI exam consisted in part of: (i) axial T2w-MRI of the pelvis: resolution 1.25 mm $\times$ 1.25 mm $\times$ 2.5 mm; field of view: 320 mm $\times$ 320 mm; slice thickness = 2.5 mm (no gap); 72 slices, and (ii) DCE-MRI—12 series of T1 weighted (T1w) at 30–34 s temporal resolution, TR $= 3.77 – 4.05$ ms, TE $= 1.69 – 1.78$ ms acquired following intravenous bolus injection of a paramagnetic gadolinium chelate—0.1 mmol of gadobenate-glumine (Bracco Diagnostics Inc., Princeton, NJ, USA) per kilogram of body weight. The contrast is administered with a power injector (Spectris, Medrad Inc., Warrendale, PA, USA) at 2 mL/s and followed by a 20-mL saline flush.

Quantitative DCE-MRI Analysis

The analysis pipeline is presented schematically in Figure 1. The DCE-MRI series were uploaded in MIM (MIM, Cleveland, OH, USA) and all subsequent analyses are performed using MATLAB R2014a (MathWorks, Natick, MA, USA) plugins. Prostate, PZ, and sample gluteus maximus (GM) volumes were manually contoured (Figure 1A). The individual steps of the analysis are described below:

- **Motion correction (Figure 1B).** Each imaging set in the DCE-MRI series was aligned to the preceding one by finding the affine transformation (shifting, scaling, and rotation) that maximized their mutual information (22). Pixels within the prostate contour and extension by 18.75 mm (15 pixels) were considered. For each pair of before and after-correction images, the sum of squared pixel differences was computed and motion correction was carried out only when this sum was smaller post-correction.

- **Identification of well-perfused (suspicious) regions of interest (ROI) in the prostate.** Non negative matrix factorization (NMF) was applied to signal-vs-time curves of all pixels within the prostate (Figure 1C) (19). Briefly, if $D$ is the data matrix, containing the individual pixel’s signal-vs-time curves in its rows (baseline corrected by the average of the pre-contrast points), then $D$ can be represented as a product of $k$ basic temporal contrast signatures $S(t)$ and their weights $W(X)$ in each pixel, i.e., $D \sim W \times S$ under the constraint that all elements of $W$ and $S$ are non-negative. $k = 3$ is estimated by Principal Component Analysis of $D$ as the number of significant Principal Components (23). The signal in the $i$th pixel in data matrix $D$ can be represented as:

$$D_i \sim W_{i,1} \times S_1 + W_{i,2} \times S_2 + \ldots + W_{i,k} \times S_k \quad (1)$$

The well-perfused pattern, $S_j$, is automatically selected from the $k$ NMF patterns as:

$$S_j = \max \left\{ AUC_{m-90}(S_m) \right\}, m = 1, \ldots, k \quad (2)$$

where $AUC_{m-90}(S_m)$ is the area under the curve (AUC) of the pattern $S_m$ between times $t1$ and $t2$. Let $W_j$ be the well-perfused (wp) contribution map ($W_{wp}$) associated with the well-perfused
 Quantitative feature extraction.

**Segmentation of well-perfused ROI.** Five methods to segment $W_{wp}$ were tested for identification of the ROI$_{wp}$, the well-perfused ROI. The first was based on Otsu thresholding (24); the others were based on a parameter $\beta = 40, 50, 60$, and 70, describing how “pure” is the pattern in a pixel (20). For instance, if $\beta = 60$, the ROI$_{wp}$ is defined by pixels for which the weight of the well-perfused pattern $W_{wp}$ is $>60\%$ of the total sum of the weights (Eq. 1). Simultaneously, the assignment of ROI$_{wp}$ to PZ vs TZ is made by using variable fraction (10, 15, and 20\%) of ROI$_{wp}$ in PZ. ROI$_{wp}$ in PZ and TZ were denoted pzROI$_{wp}$ and tzROI$_{wp}$, respectively (Figure 1E). The volumes in PZ outside of pzROI$_{wp}$ were considered normal appearing tissues PZ (NATPZ) and TZ (NATTZ).

**Quantitative feature extraction.** The signal-vs-time curve $S_{ROI}$ is reconstructed using Eq. 1 for pixels within pzROI$_{wp}$ or tzROI$_{wp}$ using $k = 3$; $S_{ROI}$ is an approximation of the average of the curves within the region. By using the NMF reconstruction this signal is effectively de-noised (19). $S_{ROI}$ and the average curve from the muscle volume $S_{GM}$ were used for quantitative analysis (Figure 1F). Six quantitative features (25, 26), summarized in Table 1 and illustrated in Figure S1 in Supplementary Material, were computed based on these two signals (Figure 1G). The features are divided in three groups:

![Flowchart](image-url)
Features extracted directly from the DCE-MRI intensity curve; (ii) Features based on the fitting of \( S_{\text{ROI}} \) and \( S_{\text{CM}} \) to a bi-exponential model; and (iii) Features calculated by fitting these curves to a late enhancement linear model. The parameters from the bi-exponential model are: initial static intensity \( s_0 \), plateau intensity \( s_{\text{m}} \), start of enhancement \( t_0 \), time-to-peak \( \tau \), and washout slope \( w_{\text{out}} \) (Figure S1 in Supplementary Material). The wash-in slope \( w_{\text{in}} \) was computed as \((s_m - s_0)/\tau\). The late enhancement linear model computed the slope and intercept of a linear fit of the intensities between \( DCE_{270} \) and \( DCE_{330} \). This slope is referred to as \( w_{\text{lin}} \).

- **Map of aggressiveness.** Let \( F \) be the value of a quantitative feature for the curve \( S_{\text{ROI}} \) in the identified volume \( ROL_{\text{wp}} \). Using the distribution of \( F \) in associations with GS, a spatial map of tumor aggressiveness was computed (Figure 1H). The 3D map of the well-perfused pattern, \( W_{\text{wp}} \), is used to generalize \( F \) for all pixels in the prostate. Let \( W_{\text{wp}}^i \) be the value of \( W_{\text{wp}} \) in the \( i \)th pixel of the prostate [Eq. (1)]. Let \( \omega = \text{mean}(W_{\text{wp}}^i, i \in ROL_{\text{wp}}) \), i.e., \( \omega \) is the average of \( W_{\text{wp}} \) in the tumor volume \( ROL_{\text{wp}} \). Thus \( W_{\text{wp}}^i/\omega = F, i \in ROL_{\text{wp}} \). Consequently, the value \( W_{\text{wp}}^i \) in each pixel can be scaled by \( F/\omega \) to generate a map of aggressiveness based on feature \( F \) and generalized to the whole prostate.

For convenience, the feature map is represented using a 1 to 10 scale, grouping the \( W_{\text{wp}}^i/F/\omega \) in 10 bins. Feature range was bound by 5th and 95th percentile of the feature values in the entire population of subjects with positive biopsies. DCE-feature scores are allocated by uniformly dividing the bounded interval in ten regions. Pixels with feature values smaller than the lower bound or larger than the upper bound were assigned a DCE-feature-score of 1 and 10, respectively.

**Statistical Analysis**

Spearman correlation coefficient (\( p \)) of the DCE-scores with the highest GS from the biopsy session was computed (patient level analysis). The GS were grouped in a clinically relevant categories, separating GS7 (\( 3+4 \)) and GS7 (\( 4+3 \)) (27). To study the ability of the features to discriminate between indolent (GS = 6) and aggressive (GS \( \geq 7 \)) lesions, the association between the quantitative features and these two classes was investigated. The significance of the median difference between groups was evaluated using Kruskal–Wallis test, followed by Dunn’s posttest. In addition, the AUC of the receiver operating characteristic (ROC) analysis was computed. A subset of the patients underwent MRI-ultrasound fused targeted (MRI-US) biopsies. The statistical test above were carried out for the DCE-scores of each biopsy location and biopsy GS (biopsy level analysis). Statistical analysis was performed using MATLAB. All tests were two-sided. Significance was set at a \( p \)-value <0.05.

**RESULTS**

**Patients**

The flow diagram of inclusion and exclusion criteria of the analyzed patients is presented in Figure S2 in Supplementary Material. Nine patients (9/71, 12%) were excluded because: four patients lacked complete DCE-MRI series and five had suboptimal contrast data due to acquisition artifacts or incomplete contrast administration. The clinical characteristics of the analyzed cohort are summarized in Table S1 in Supplementary Material. The highest GS from the biopsy session was used.

**Motion Correction**

For each pixel in the dataset, \( DCE_N \) was aligned to \( DCE_{N-30} \) (\( N = 90, 120, \ldots, 330 \)) and motion was quantified as the mean absolute pixel gray scale-intensity difference between \( DCE_N \) and \( DCE_{N-30} \), before and after correction. For 27 patients (44%), the movement correction procedure resulted in essentially no change (change of pixels squared differences before and after: median = 0.02%; range = -2.38 to 1.51%). For 35 patients (56%), the procedure yielded significant improvement: median = 9.93%, range = 2.61–46.84%. The procedure is illustrated for the patient with the largest correction (Figure S3 in Supplementary Material).

**Identification and Delineation of Well-Perfused (Suspicious) ROI in the Prostate**

All five segmentation methods resulted in significant correlations between the volumes of \( ROL_{\text{wp}} \) and GS. The Spearman correlation \( p \) of the volume of \( ROL_{\text{wp}} \) and GS (\( 6, 3+4, 4+3, \geq 8 \)), \( p \)-value, and the number of patients assigned to PZ or TZ, or rejected due to volumes less than 0.5 cc are presented in Table 2. While in general, with increasing \( \beta \), the correlations with GS increased, the resulting smaller \( ROL_{\text{wp}} \) volumes caused a large number of patients to be rejected due to \( ROL_{\text{wp}} < 0.5 \) cc. \( \beta = 60 \) and 10% PZ vs TZ were selected. The median size of the well-perfused region \( ROL_{\text{wp}} \) across the patients was 1.95 cc (range 0.23–12.21 cc). Following 0.05 cc cleanup for disconnected small volumes, the resulting volumes \( ROL_{\text{wp}} \) were on average 18.19% smaller and ranged in size between 0.16 and 11.52 cc. Eight patients with \( ROL_{\text{wp}} < 0.5 \) cc were eliminated from further processing. For the remaining 54 patients, the mean volume of \( ROL_{\text{wp}} \) was 2.57 cc (median = 1.84 cc, range 0.51–11.52 cc). Forty-one (76%) of the tumors were in the PZ (\( pzROL_{\text{wp}} \)). The mean volume of \( pzROL_{\text{wp}} \) was 1.08 cc (median = 0.80 cc, range 0.15–5.01 cc) and the mean volume of \( tzROL_{\text{wp}} \) was 3.09 cc (median = 1.28 cc, range 0.80–11.52 cc). The distributions of \( pzROL_{\text{wp}} \) volumes in association with GS divided in three (\( 3, 3+4 > 4+3 \)) and four groups

| Threshold (%) of the suspicious ROIs in PZ | PZa Statistics Otsu 40% 50% 60% 70% |
|-----------------------------------------|----------------------------------|
| 10%                                    | Spearman’s \( p \) 0.22 0.14 0.25 0.34 0.43 |
|                                        | \( p \)-value 0.155 0.307 0.087 0.031 0.086 |
|                                        | P2/T2/rejected (N) 45/15/0 53/7/0 48/9/3 40/12/8 17/11/32 |
| 15%                                    | Spearman’s \( p \) 0.19 0.13 0.27 0.39 0.43 |
|                                        | \( p \)-value 0.230 0.364 0.096 0.022 0.086 |
|                                        | P2/T2/rejected (N) 40/20/0 51/9/0 40/17/3 35/17/8 17/11/32 |
| 20%                                    | Spearman’s \( p \) 0.14 0.14 0.23 0.33 0.43 |
|                                        | \( p \)-value 0.420 0.553 0.166 0.073 0.443 |
|                                        | P2/T2/rejected (N) 34/26/0 46/14/0 38/19/3 31/21/8 15/13/32 |

\( PZ \), peripheral zone; TZ, transition zone.

*Threshold (%) of the suspicious ROIs in PZ.
(6, 3 + 4, 4 + 3, 8 − 10) are shown in Figure 2A. In both cases, Spearman correlation coefficients were significant.

**Associations of Quantitative Features with Prostate Cancer Aggressiveness (Patient Level Analysis)**

Six quantitative features (Table 1) were computed based on the signal $S_{ROI}$ for the patients with suspicious area in PZ (pzROIwp). The correlations between these features and the highest GS (6, 3 + 4 and >3 + 4) are presented before and after normalization with the signal from the muscle reference $S_{GM}$ (Figures 2B, C). Note that the correlations with GS improve substantially following normalization with the muscle signal, reaching significance ($p < 0.05$) in all cases but one. When GS is divided in four groups: 6, 3 + 4, 4 + 3, 8 − 10 the same five features remained significant (Figure 2D). It should be noted that none of the features were significant for tzROIwp (data not shown). In addition, comparisons including the distribution of the quantitative features in NATPZ and NATTZ we carried out (Figure S4 in Supplementary Material). Their corresponding AUC for discrimination between NATPZ and pzROIwp ranged between 0.62 and 0.99. AUCs of DCE-scores in tzROIwp were also high. In view of the small number of lesions in TZ, however, these results should be treated with caution.

**Correlation of Quantitative Features with MRI-US Biopsies (Biopsy Level Analysis)**

Sixteen patients underwent MRI-US biopsies and had a total of 35 positive biopsies (Figure S5 in Supplementary Material). After

![Figure 2](image_url)
confirmation of the location of the actual biopsy, the region with needle tracks was back-projected onto T2w. The overlap between the biopsy region and the well-perfused region ROI$_{wp}$ was denoted as usROI$_{wp}$. Quantitative features were computed for each biopsy in PZ (29/35) using the average signal in usROI$_{wp}$. The associations of the six features for PZ tumors and the targeted biopsy GS (divided in three and four groups) are presented in Figures 3A,B. The same four features were significant using three, four GS groups and when tumors were split into indolent (GS = 6) and aggressive (GS ≥ 7) [wash-in ratio reached marginal ($p = 0.051$) significance] (Figure 3C). The features resulted in AUC for classifying indolent vs aggressive PZ lesions ranging between 0.85 and 0.95 (Figure 3D).

**Map of Aggressiveness**

Using $W_{wp}$ and the DCE-score $F$ from ROI$_{wp}$, each pixel in the prostate was scored for aggressiveness using 1 to 10 scale. In Figures 4A,B, two axial slices of the prostate are shown with indicated regions representing the intersection of the identified well-perfused region ROI$_{wp}$ and the biopsy locations. A schematic representation of the prostate with the biopsy needle tracks (yellow) in the target volumes (1 in the green, 2 in the red, and 1 in the blue target) is depicted in Figure 4C. On pathology review, the biopsies were assigned GS = 6 (green target) and GS = 7 (for both biopsies in the red target). Map of aggressiveness was generated for early AUFC ratio feature. In Figures 4D,E, the map is overlaid on the patient axial MRIs slices. The areas of the positive biopsies are clearly identified. The color scheme of the maps is given on the right. There are no pixels with DCE-scores 9 and 10, indicating lack of areas with high GS. The highest DCE-score on the maps (left to right) was 6 and 8, consistent with the biopsy findings.

The MRI-US dataset was utilized to confirm the accuracy of the global map of aggressiveness. On one hand, the map of aggressiveness feature$_{wp}$ was generated using only $W_{wp}$ and $F$. On the other
hand, the feature value for each biopsy ROI was estimated in the previous section using usROIwp. In Figure S6 in Supplementary Material, the x-axis corresponds to the feature computed using usROIwp. The y-axis is the mean value of the map of aggressiveness over the region of the biopsy, mean [feature,wp(mrusROI)]. There was an excellent concordance between these two estimates for each biopsy ROI (n = 29) for each feature: the correlation coefficients ranged between 0.85 and 0.99; the slope for the linear fit ranged between 0.87 and 0.98. This graph also confirms the co-localization of the “hot” spots of the map of aggressiveness with the biopsy location.

**DISCUSSION**

DCE-MRI plays an ancillary role in tumor assessment to T2-weighted (T2w) and DWI in the contemporary recommendations for prostate cancer review and scoring in PI-RADSv2. The diminished role of DCE-MRI is confounded by: (i) difficulties for radiologists to quantitatively assess multiple DCE-MRI series via image viewing; and (ii) lack of reproducibility of the quantitative parameters when modeling approaches are used. In addition, other factors, such as chronic inflammation and differential characteristics of the prostate zones further complicate the DCE-MRI interpretation. The thesis of this work is that DCE-MRI can reliably identify and consistently score prostate cancer lesions if the region of well-perfused tissue is properly delineated and sensible quantitative features, using internal signal normalization are used.

The presented approach considers the signal-vs-time curves from each pixel in the dataset and an unsupervised PR technique is used to identify the pixels with the characteristic for tumor perfusion pattern. Quantitative features are calculated from a representative signal-vs-time curve from these pixels. Several of these features, especially after normalization with signal from the muscle, were significantly correlated with biopsy GS, and differentiated indolent (GS = 6) from aggressive tumors (GS ≥ 7). For instance, Litjens et al. (28) found that the \( \tau \)-induced volume and wash-out had a large relative importance in their ROC analysis for classification of cancer (normal/benign). Vos et al. (10) found that wash-in and wash-out were statistically different between low-grade (GS = 6) and high-grade [GS > 7(4 + 3)] in the PZ. The Area under the Receiver Operating Characteristics Curve (AUROC) for indolent vs. aggressive in this work were 0.72 for wash-in and 0.65 for wash-out. In comparison, after normalization by muscle, the AUROC for wash-in and wash-out of 0.85 and 0.88 are reported here. Chen et al. found a significant correlation between wash-out and GS, with an AUROC for indolent/aggressive classification of 0.88 (26). Significant correlation and coincidentally the same AUROC of 0.88 is reported here. It should be noted that unlike these previous reports, where few significant
features are found, the majority of the evaluated features here were significantly correlated with GS, both on patient and biopsy level analysis. This is attributed to the robustness of well-perfused ROI selection and fitting a single DCE curve of high SNR, rather than pixel-by-pixel in the ROI (10). This reduces the errors associated with noise, data acquisition and motion artifacts.

Here, a novel pipeline for automatic generation of a well-perfused ROI is presented. The method performs well in datasets acquired at low temporal resolution. Most current research and PI-RADS guidelines suggest that high-temporal resolution be used. While this is a requirement for compartment model analysis, the straight-forward features extracted here are significantly correlated with GS even at low temporal resolution ($\Delta t = 30$ s).

This study has several limitations. First, this is a retrospective study with all inherent limitations of the design. Second, the application of the thresholds require contours of PZ and TZ. The use of prostate atlas will decrease significantly the need of manual contouring (29). And finally, the generalizability of the determined thresholds to other MRI sequences, vendors, magnetic field strengths, and coils (endorectal vs body) should be investigated. Until then, it should be assumed that the thresholds are valid for DCE data, acquired under identical conditions.

In conclusion, a quantitative approach for DCE-MRI analysis is developed and the resultant map of aggressiveness is integrated in radiotherapy/radiology imaging software as a guide for targeted biopsies and treatments. In RT of prostate cancer, dose escalation for prostate cancer has been shown to reduce biochemical failure (30). While dose escalation also has been shown to reduce the need for androgen deprivation in intermediate to high risk patients (4, 31, 32), when the entire prostate is dose escalated, there is an increased risk of secondary adverse events. Dose escalation only to determine prostate habitas has the potential to improve tumor control with less toxicity than when the entire prostate is dose escalated.

**ETHICS STATEMENT**

This study was carried out in accordance with the recommendations of the Institutional Review Board (IRB) of the University of Miami. The IRB approved a protocol for retrospective review of mpMRI exams from prostate cancer patients. The IRB waived the need for informed consent.

**AUTHOR CONTRIBUTIONS**

RS, AP, and NP conceived the study; AP, MA, and SP provided patients; NP, RS, FC, and OK collected and assembled data; NP, RS, BM, FM, RC, and AP conducted data analysis and interpretation; NP, RS, and AP wrote the manuscript; All authors reviewed the manuscript for intellectual content and approved the final version.

**FUNDING**

This publication was supported by Grants R01CA189295 and R01CA190105 from the National Cancer Institute.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at http://www.frontiersin.org/article/10.3389/fonc.2017.00259/full#supplementary-material.

**REFERENCES**

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin (2015) 65:5–29. doi:10.3322/caac.21254
2. Rodda S, Tydesley S, Morris WJ, Keyes M, Halperin R, PaI H, et al. ASCENDE-RT: an analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. *Int J Radiat Oncol Biol Phys* (2017) 98:286–95. doi:10.1016/j.ijrobp.2017.02.027
3. Lips IM, van der Heide UA, Haustermans K, van Lin EN, Pos F, Franken SP, et al. Single blind randomized phase III trial to investigate the benefit of a focal lesion ablative microboost in prostate cancer (FLAME-trial): study protocol for a randomized controlled trial. *Trials* (2011) 12:255. doi:10.1186/1745-6215-12-255
4. Bauman G, Haider M, Van der Heide UA, Menard C. Boosting imaging defined dominant prostatic tumors: a systematic review. *Radiother Oncol* (2013) 107:274–81. doi:10.1016/j.radonc.2013.04.027
5. Ocak I, Bernardo M, Metzger G, Barnett L, Pinto P, Albert PS, et al. Dynamic contrast-enhanced MRI of prostate cancer at 3 T. *Eur Urol* (2012) 61:217–22. doi:10.1016/j.eururo.2011.01.107
6. Bauman G, Haider M, van der Heide UA, Pos F, Franken SP, et al. Single blind randomized phase III trial to investigate the benefit of a focal lesion ablative microboost in prostate cancer (FLAME-trial): study protocol for a randomized controlled trial. *Trials* (2011) 12:255. doi:10.1186/1745-6215-12-255
7. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Horsman MR, et al. Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of a diffusible tracer: standardized quantities and symbols. *J Magn Reson Imaging* (1999) 10:223–32. doi:10.1002/(SICI)1522-2586(199909)10:3<223::AID-JMRI2>3.0.CO;2-S
8. Parra et al. DCE-MRI Scoring of Prostate Cancer
9. Isebaert S, Van den Bergh L, Haustermans K, Joniau S, Lerut E, De Wever L, et al. Multiparametric MRI for prostate cancer localization in correlation to whole-mount histopathology. *Eur Urol* (2011) 59:255. doi:10.1186/1477-5877-8-2094
10. Mclean RA, Sanders WL, Stroup WW. A unified approach to mixed linear-models. *Am Stat* (1991) 45:54–64. doi:10.1080/00031305.1991.10475767
11. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, et al. Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of a diffusible tracer: standardized quantities and symbols. *J Magn Reson Imaging* (1999) 10:223–32. doi:10.1002/(SICI)1522-2586(199909)10:3<223::AID-JMRI2>3.0.CO;2-S
12. Leach MO, Brindle KM, Evelhoch JL, Griffiths JR, Horsman MR, Jackson A, et al. The assessment of antiangiogenic and anti-vascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. *Br J Cancer* (2005) 92:1599–610. doi:10.1038/sj.bjc.6602550
13. Isebaert S, De Keyzer F, Haustermans K, Lerut E, Roskams T, Vaes D, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusible tracer: standardized quantities and symbols. *J Magn Reson Imaging* (1999) 10:223–32. doi:10.1002/(SICI)1522-2586(199909)10:3<223::AID-JMRI2>3.0.CO;2-S
14. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, et al. Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of a diffusible tracer: standardized quantities and symbols. *J Magn Reson Imaging* (1999) 10:223–32. doi:10.1002/(SICI)1522-2586(199909)10:3<223::AID-JMRI2>3.0.CO;2-S
15. Huang W, Li X, Chen Y, Li X, Chang M, Oborski M, et al. Variations of dynamic contrast-enhanced magnetic resonance imaging in evaluation of
breast cancer therapy response: a multicenter data analysis challenge. *Transl Oncol* (2014) 7:153–66. doi:10.1593/tho.13838

16. Huang W, Chen Y, Fedorov A, Li X, Jaimovich GH, Malyarenko DI, et al. The impact of arterial input function determination variations on prostate dynamic contrast-enhanced magnetic resonance imaging pharmacokinetic modeling: a multicenter data analysis challenge. *Tomography* (2016) 2:56–66. doi:10.18383/j.tom.2015.00184

17. Aerts HJ, Jaspers K, Backes WH. The precision of pharmacokinetic parameters in dynamic contrast-enhanced magnetic resonance imaging: the effect of sampling frequency and duration. *Phys Med Biol* (2011) 56:5665–78. doi:10.1088/0031-9155/56/17/013

18. Othman AE, Falkner F, Martirosian P, Schraml C, Schwentner C, Nickel D, et al. Optimized fast dynamic contrast-enhanced magnetic resonance imaging of the prostate: effect of sampling duration on pharmacokinetic parameters. *Invest Radiol* (2016) 51:106–12. doi:10.1097/RLI.0000000000000213

19. Stoyanova R, Huang K, Sandler K, Cho H, Carlin S, Zanzonico PB, et al. Mapping tumor hypoxia in vivo using pattern recognition of dynamic contrast-enhanced MRI data. *Transl Oncol* (2012) 5:437–47. doi:10.1593/tho.12319

20. Chang YC, Ackerstaff E, Tschudi Y, Jimenez B, Foltz W, Fisher C, et al. Delineation of tumor habitats based on dynamic contrast enhanced MRI. *Sci Rep* (2017) 7:9746. doi:10.1038/s41598-017-09932-5

21. Parra NA, Orman A, Padgett K, Casillas V, Punnen S, Abramowitz M, et al. Dynamic contrast-enhanced MRI for automatic detection of foci of residual or recurrent disease after prostatectomy. *Strahlenther Onkol* (2017) 193:13–21. doi:10.1007/s00066-016-1055-z

22. Mattes D, Haynor DR, Vesselle H, Lewellen TK, Eubank W. PET-CT image registration in the chest using free-form deformations. *IEEE Trans Med Imaging* (2003) 22:120–8. doi:10.1109/TMI.2003.809072

23. Abdoli A, Stoyanova R, Maudsley AA. Denoising of MR spectroscopic imaging data using statistical selection of principal components. *MAGMA* (2016) 29:811–22. doi:10.1007/s10334-016-0566-z

24. Otsu N. Threshold selection method from gray-level histograms. *IEEE Trans Syst Man Cybern* (1979) 9:62–6. doi:10.1109/TSMC.1979.4310076

25. Huisman HJ, Engelbrecht MR, Barentsz JO. Accurate estimation of pharmacokinetic contrast-enhanced dynamic MRI parameters of the prostate. *J Magn Reson Imaging* (2001) 13:607–14. doi:10.1002/jmri.1085

26. Chen YJ, Chu WC, Pu YS, Chueh SC, Shun CT, Tseng WY. Washout gradient in dynamic contrast-enhanced MRI is associated with tumor aggressiveness of prostate cancer. *J Magn Reson Imaging* (2012) 36:912–9. doi:10.1002/jmri.23723

27. Brimo F, Montironi R, Egevad L, Erbersdobler A, Lin DW, Nelson JR, et al. Contemporary grading for prostate cancer: implications for patient care. *Eur Urol* (2013) 63:892–901. doi:10.1016/j.eururo.2012.10.015

28. Litjens G, Debats O, Barentsz J, Karssemeijer N, Huisman H. Computer-aided detection of prostate cancer in MRI. *IEEE Trans Med Imaging* (2014) 33:1083–92. doi:10.1109/TMI.2014.2303821

29. Nelson AS, Piper J, Curry K, Swallen A, Padgett K, Pollack A, et al. Evaluation of an atlas-based segmentation method for prostate and peripheral zone regions on MRI. *Med Phys* (2015) 42:3606–3606. doi:10.1118/1.4923601

30. Kuban DA, Levy LR, Cheung MR, Lee AK, Choi S, Frank S, et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? *Int J Radiat Oncol Biol Phys* (2011) 79:1310–7. doi:10.1016/j.ijrobp.2010.01.006

31. Demanes DJ, Brandt D, Schour L, Hill DR. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation. *Am J Clin Oncol* (2009) 32:342–7. doi:10.1097/COC.0b013e31818cd277

32. Dattoli M, Waliner K, True L, Bostwick D, Cash J, Sorace R. Long-term outcomes for patients with prostate cancer having intermediate and high-risk disease, treated with combination external beam irradiation and brachytherapy. *J Oncol* (2010) 2010:1–6. doi:10.1155/2010/471375

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2017 Parra, Pollack, Chinea, Abramowitz, Marples, Munera, Castillo, Kryvenko, Punnen and Stoyanova. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.